An authoritative synopsis of the Infinity Pharmaceuticals class action lawsuit

Contact Infinity Pharmaceuticals stock loss lawyer Timothy L. Miles about an Infinity Pharmaceuticals lawsuit

If you suffered losses in Infinity Pharmaceuticals stock-contact Timothy L. Miles for free case evaluation.

The Infinity Pharmaceuticals class action lawsuit is a critical legal proceeding in the realm of pharmaceuticals and investment. This legal case involves claims of alleged securities fraud against Infinity Pharmaceuticals, a biotechnology company based in Cambridge, Massachusetts. The core of the lawsuit centers around accusations that Infinity Pharmaceuticals made materially false and misleading statements regarding its business and future prospects.

The Infinity Pharmaceuticals class action lawsuit seeks to represent purchasers or acquirers of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) securities between January 5, 2022 and July 24, 2023, inclusive (the “Class Period”).  Captioned Dilbarian v. Infinity Pharmaceuticals, Inc., No. 23-cv-11865 (D. Mass.), the Infinity Pharmaceuticals class action lawsuit charges Infinity Pharmaceuticals and certain of its top executive officers with violations of the Securities Exchange Act of 1934.   The complaint alleges that during this period, Infinity Pharmaceuticals made false and misleading statements and failed to disclose material adverse facts about the company’s business, operations, and prospects. 

The Infinity Pharmaceuticals class action lawsuit alleges that the company made false and/or misleading statements. Specifically, the lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that Infinity Pharmaceuticals falsely claimed that there were viable partnership opportunities for eganelisib’s development, but the MARIO-4 and MARIO-P studies would be initiated after the establishment of these partnerships.

On February 23, 2023, Infinity Pharmaceuticals announced that it had entered into a merger agreement with MEI Pharma, Inc (“MEI”).  The proposed transaction was all stock, pursuant to which Infinity Pharmaceuticals shareholders would receive shares of MEI common stock and Infinity Pharmaceuticals would become a wholly-owned subsidiary of MEI, with outstanding equity post-closing being held 58% by MEI shareholders and 42% by Infinity Pharmaceuticals shareholders.  Defendant Adeline Perkins, Chief Executive Officer of Infinity Pharmaceutics, stated Infinity Pharmaceuticals would “prioritize head and neck cancer.”  On this news, the price of Infinity Pharmaceuticals stock declined nearly 49%.

To put it succinctly, the Infinity Pharmaceuticals class action lawsuit is a significant legal proceeding that underscores the importance of corporate transparency and accountability. It serves as a stark reminder to pharmaceutical companies about the ramifications of providing false or misleading information about their products and operations. For potential investors, it underlines the need for thorough due diligence before making investment decisions. 

As the lawsuit moves through the legal system, it will be closely watched by stakeholders in the pharmaceutical industry and the investing community at large. The outcome of the Infinity Pharmaceuticals class action lawsuit could potentially have far-reaching implications for how companies in the sector communicate with their investors and disclose information about their operations and products. 

In order to protect your investment, it may also be beneficial to consult with legal professionals who practice securities litigation. They can provide you with advice and guidance on how to navigate through this class action lawsuit and protect your interests as a shareholder. They can help you understand your rights as a shareholder and assist you in evaluating whether or not to participate in the Infinity Pharmaceuticals class action lawsuit. 

​Look for a securities lawyer with experience, high ethical standards, verifiable credentials, and a trustworthy reputation among his peers and the judiciary, as well as testimonials from previous clients and awards and recognitions. ​​​​

One name that immediately pops up is nationally known and widely respected Nashville stock loss lawyer Timothy L.  Miles, who has valuable experience working on some of the nation's largest securities class actions and has received numerous awards, mostly due to his high ethical standards, including most recently being named a Top 25 Class action lawyer by the National Trial Lawyers Association, and has maintained an AV rating in securities litigation from Martindale-Hubble since 2014, a trusted legal rating service for over 130 years and was recently named a 2023 Elite Lawyer of the South by Martindale-Hubble for the fifth year in a row, and was a recipient of Avvo Client's Choice Award in 2021.  Therefore, you may start by contacting a trusted, well-respected and ethical securities lawyer such as Mr. Miles. ​
​
In conclusion, the Infinity Pharmaceuticals class action lawsuit encapsulates the intricate intersection of investment, pharmaceuticals, and corporate accountability. The resolution of this case will not only determine the fate of Infinity Pharmaceuticals but may also set precedents for future legal proceedings in the industry. It is a crucial case that sheds light on the responsibilities that pharmaceutical companies owe to their investors and the potential consequences of breaching those duties.

As a reminder,  Lead plaintiff motions for the Infinity Pharmaceuticals class action lawsuit must be filed with the court no later than October 16, 2023. If you suffered losses in Infinity Pharmaceuticals stock, contact Infinity Pharmaceuticals stock loss lawyer Timothy L. Miles today for a free case evaluation about a class action against Infinity Pharmaceuticals.

​Call today and see what an Infinity Pharmaceuticals stock loss lawyer can do for you if you suffered losses in Infinity Pharmaceuticals stock.

---

Infinity Pharmaceuticals stock loss lawyer Timothy L. Miles

Nashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing  shareholders, employees,  and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors,shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association,​Class Action:  Class Action: Top 9National Trial Lawyers, National Trial Lawyers Association (2023), a superb ratedattorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM  (2019-2022); America’s Most Honored Lawyers 2020 – Top 1% by America’s Most Honored (2020-2022).  Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more.  Please visit our website or call for free anytime.

CONTACT                                                      
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
​300 Centerview Dr., #247
Brentwood, TN 37027
Phone: (855) 846-6529
​Email: [email protected]